aibioCullinan unit ends MIT license for CLN-617 after dropping the program
Tickers CGEM
Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026.
Key facts
- Company
- Cullinan Therapeutics, Inc. (NASDAQ: CGEM)
- News type
- Distress
- Primary source
- Cullinan Therapeutics, Inc. 8-K (2025-11-21)
Cullinan Amber Corp., a subsidiary of Cullinan Therapeutics, Inc. (CGEM), notified the Massachusetts Institute of Technology (MIT) on November 18, 2025 that it is ending its Exclusive Patent License Agreement. The agreement is dated December 20, 2019, and has been amended from time to time. The termination is effective as of February 18, 2026.
The company took the step in connection with its decision not to pursue further development of CLN-617. Under the license, MIT had granted the company exclusive worldwide rights to the technology underlying CLN-617, so that it could develop a cancer immunotherapy product worldwide. The 8-K was filed on November 21, 2025.
As part of the termination, the company will return the licensed patent rights for the technology underlying CLN-617 to MIT.